Illumina Stock Surges 94.9% YTD: What's Behind the Rally?

Sep 24, 2026 4:45 PM · YahooFinance

Illumina ILMN shares have shown impressive momentum so far this year, surging 94.9%. The stock has outpaced the industry's 8.6% gain and the S&P 500 Composite's 13.1% rise.

Carrying a Zacks Rank #3 (Hold) at present, the renowned genomics company is making solid progress across its core sequencing, multiomics, and services, data and software businesses, supporting a stronger 2026 outlook. The company's clinical business is gaining momentum as sequencing adoption expands across key applications. Illumina's strong liquidity and manageable debt position support continued investment.

San Diego, CA-based Illumina provides sequencing and array-based solutions for genetic and genomic analysis. The products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. Its customers include leading genomic research centers, academic institutions, government laboratories, hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic and consumer genomics companies. In January 2026, Illumina acquired SomaLogic, a proteomics company that provides high-throughput protein measurement technology and related data analysis services.

The rally in the company's share price can be linked to strong progress across three pillars — growth in its core sequencing business, expansion into multiomics, and broader services, data and software capabilities. Following the June 2024 GRAIL spin-off, Illumina remains focused on these areas as it works to drive sustainable growth. Second-quarter 2026 revenues rose 9.5% year over year to $1.16 billion, supported by continued demand across the business.

Image Source: Zacks Investment Research

Excluding China, currency and acquisition effects, Rest of World organic revenues increased 8.1%, reflecting broad-based growth, led by clinical markets. Management raised full-year 2026 revenue guidance to $4.60-$4.64 billion and adjusted earnings per share (EPS) guidance to $5.30-$5.40 while maintaining adjusted operating margin guidance of 23.4%-23.6%.

Illumina continues to benefit from wider adoption of NGS-based diagnostics and sequencing-intensive clinical applications. Clinical markets accounted for approximately 65% of sequencing consumables revenues in the second quarter of 2026. For the first half of 2026, clinical consumables growth was roughly 17%, representing a modest acceleration from the second half of 2025. As customers add capacity for applications such as oncology and whole-genome sequencing, this higher sequencing intensity should support consumables demand beyond the current instrument placement cycle.

NovaSeq X remains the main platform supporting Illumina's high-throughput sequencing growth. The company placed more than 95 NovaSeq X systems in the second quarter of 2026, reflecting continued capacity expansion by clinical customers. Nearly 83% of high-throughput volumes and 59% of revenues had transitioned to NovaSeq X, while 78% of clinical volume was on the platform.

Illumina's balance sheet remained in good shape at the end of the second quarter, with approximately $1.17 billion in cash, cash equivalents and short-term investments. Current debt was $500 million, while long-term debt remained at $1.49 billion, putting gross debt at roughly 1.6 times last-12-month EBITDA. The combination of strong liquidity and moderate leverage gives Illumina flexibility to invest in its business while managing its financial obligations.

lllumina continues to operate in a higher-cost environment shaped by tariffs, freight and component inflation. China remains a key demand headwind for the company, with regulatory uncertainty continuing to weigh on the business. Until the restrictions ease, lower activity in the region can limit instrument placements, installed-base expansion and subsequent consumables pull-through, reducing Illumina's ability to capture growth from that market.

The Zacks Consensus Estimate for ILMN's 2026 and 2027 EPS calls for increases of 10.7% and 13.8% year over year, respectively, to $5.36 and $6.10. In the past 60 days, the consensus estimate for the 2026 EPS has risen 0.4%.

Revenues for 2026 are projected to grow 6.3% to $4.62 billion and another 6.7% to $4.93 billion in 2027.

Some better-ranked stocks in the broader medical space are Veracyte VCYT, Globus Medical GMED and Teleflex TFX.

Veracyte has an earnings yield of 4.7% against the industry's negative 1.4% yield. Shares of the company have risen 33.6% compared with the industry's 4.7% growth. VCYT's earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.

VCYT sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks here.

Globus Medical, sporting a Zacks Rank #1, has an earnings yield of 6.7% against the industry's negative 1.4% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 34.3% compared with the industry's 4.7% growth over the past year.

Teleflex, carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 20.7% compared with the industry's 14.5% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX shares have gained 4.1% compared with the industry's 4.7% growth over the past year.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report